Moxifloxacin (Avelox, BAY12-8039)

Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

Bioavailability, Food Effect and Safety, Tolerability of a New Oral Suspension in Comparison to the Marketed Moxifloxacin Tablet in Healthy Adults

Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection

A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease

BAY12-8039: 5 Days for Sinusitis vs Placebo

Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem

Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis

AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs

VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis

SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)

Greatest International Antiinfective Trial With Avelox

CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients

Avelox in Complicated Skin and Skin Structure Infections

Moxifloxacin i.v. in the Treatment of Complicated Intra-Abdominal Infection (cIAI)

Risk of Acute Liver Injury in Users of Antimicrobials